Gali Weinreb On Thursday, November 27th, 2014

Compugen CEO Dr. Cohen-Dayag: ‘Today, We Dare to Talk about Curing Cancer, That Is The Goal’

In recent years, cancer research and treatment centers have been awash with a wave of new, exciting developments, under the umbrella of “immunotherapy, ” in other words, harnessing the immune system More...

Gali Weinreb On Monday, November 24th, 2014

China’s Tsing Capital to invest in Israeli cleantech

– We plan to make investments by the end of the year, says Tsing Capital’s Don Ye. –   “Cleantech is probably the most important segment in cooperation between Israel and China, More...

Gali Weinreb On Sunday, November 23rd, 2014

Universal flu vaccine co BiondVax mulls NY IPO

– BiondVax is exploring two options – either a conventional offering or listing American Depositary Receipts. –   Universal flu vaccine developer BiondVax Pharmaceuticals Ltd. (TASE:BNDX) More...

Gali Weinreb On Thursday, November 13th, 2014

Drug developer NeuroDerm to begin Nasdaq IPO

–  The Israeli Parkinson’s disease treatment developer is seeking $58-72 million at a company value of $290 million. –   Rehovot-based NeuroDerm, which has developed a transdermal drug More...

OPKO
Gali Weinreb On Monday, November 10th, 2014

Phillip Frost seeks SciGen reverse merger

–  The Opko Health Chairman hopes to attain a value of over $100 million for the Rehovot-based vaccination developer.   Vaccination company SciGen, controlled by Opko Health Inc. (NYSE: OPK; TASE: More...

Gali Weinreb On Tuesday, October 21st, 2014

Israeli, Jordanian researchers team on leishmaniasis treatment

– The project brings together a consortium of parties from Israel, Jordan, and Switzerland for the treatment of the parasitic disease. – Researchers from Israel and Jordan are seeking a treatment More...

Gali Weinreb On Wednesday, October 15th, 2014

Ebola anxiety boosts Protalix again

– Smallcap investor network report: An experimental Ebola drug can be produced on Protalix‘s vegetable platform. Anxiety about the Ebola disease increased again at the end of last week, when More...

Gali Weinreb On Thursday, October 2nd, 2014

VBL Therapeutics raises $40 million in revived Nasdaq IPO

– After the fiasco of the failed IPO in August, the drug development company scaled down the offering. VBL Therapeutics has raised $40 million at a company value of $120 million in a revived IPO on Nasdaq. More...

Gali Weinreb On Wednesday, September 10th, 2014

Investor files class action on Andromeda biotech

– Investor Mori Arkin: If Hyperion overlooked weak points in the data, it’s their mistake. – The Andromeda affair, in which an Israeli company is being accused of forging clinical More...

Gali Weinreb On Monday, September 8th, 2014

Len Blavatnik donates $20 million to Tel Aviv University

– The donation will fund drug development, computer science, cyber research, movie production and more. –   The Blavatnik Family Foundation is donating $20 million to Tel Aviv University More...

Wordpress site Developed by Fixing WordPress Problems